Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.
about
PLK-1 Targeted Inhibitors and Their Potential against TumorigenesisPlk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell linesPLK1, A Potential Target for Cancer TherapyStructure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoniIdentification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assayTherapeutic Implications of Black Seed and Its Constituent Thymoquinone in the Prevention of Cancer through Inactivation and Activation of Molecular Pathways.Function of survivin in trophoblastic cells of the placenta.Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibitionMitotic centromere-associated kinesin (MCAK): a potential cancer drug target.Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer TreatmentInhibitors of the Polo-Box Domain of Polo-Like Kinase 1.Kizuna is a novel mitotic substrate for CDC25B phosphataseIdentification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domainCdk1 and Plk1 mediate a CLASP2 phospho-switch that stabilizes kinetochore-microtubule attachmentsRecent Advances and New Strategies in Targeting Plk1 for Anticancer TherapyB-cell lymphoma 6 promotes proliferation and survival of trophoblastic cellsImpact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.Polo-like kinase-1 in DNA damage response.Current assessment of polo-like kinases as anti-tumor drug targets.Understanding the Polo Kinase machine.The role of Plk3 in oncogenesis.Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.Polo-like kinase 1 regulates the stability of the mitotic centromere-associated kinesin in mitosis.pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner.p21Waf1/Cip1 deficiency causes multiple mitotic defects in tumor cells.Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.The activity regulation of the mitotic centromere-associated kinesin by Polo-like kinase 1Polo-like kinase 1 as target for cancer therapy.Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.Polo-like kinases in AML.Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators.Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.Upregulation of C/EBPα contributes to colorectal cancer growth, metastasis and indicates poor survival outcome
P2860
Q26777811-68855EA9-EBF1-47F3-A015-524619A8981FQ27334288-97EB6404-4193-494F-BFEF-F62E7576295AQ28078772-4727D37E-5C37-41C6-9A19-154D01731E18Q28552326-47A90FA6-1D99-44E5-8943-A3E0FC8F3F42Q28820936-109C993D-4703-434E-8216-1B81E1A78242Q33736242-F08F1096-9C54-44D1-82E7-2289825682A0Q34998646-DF844B59-19A7-46E8-ADB6-D640DE6E96D6Q35740037-453CAD75-D9B9-4925-A62A-44C73816E89DQ35764416-53039A68-D304-4D42-8DB6-D766BF74BE4DQ35801683-B4D0FCF2-981B-4F08-BFF0-E2CBD4330512Q35867866-F07D39DA-68AB-42E9-8E65-B2BCA452E772Q36189477-14663C18-66B4-4D83-AF53-997D3DBB2082Q36207913-169EBB0C-C454-40A0-9B73-FAE30E70DF23Q36317230-183D2A8C-EBAF-4754-B757-83B51FE3DD9DQ36386336-CC21A58B-21FF-414B-8919-7AA2418B5B07Q36839342-752A14C9-77F9-4C6B-B79D-A8300F66F789Q37708943-7B9F8BE4-4C9C-4481-B019-E7BF81B47C0CQ38129174-A87EE90C-E92E-4A1C-8F5C-3A85D6F790D2Q38199282-2ADE4E18-05A7-4CFF-B520-B1D078C3DF25Q38211244-7E673189-633C-43A6-946C-38339DFCC355Q38331761-A61B15BE-0F62-4E3F-BAAC-B6F166F96A34Q38444150-9CF19240-1354-4328-99C5-31E5060A991DQ38872725-F24EC514-2B74-4497-90E4-F4467E73E36DQ38961886-C9F48B8E-1DB3-41FE-AE3B-2447C8981B25Q38984499-060CEFF5-2C30-48F7-94A6-4A9F20BC1868Q39042925-3549C785-2737-4ECD-BB03-652CEF17961AQ39045570-455DBFCF-C464-43FC-A5CB-65B6A5B0C0ABQ41461306-F737CFFF-528D-48CF-83CF-DBDEF5A0492FQ41694208-82F9E3D3-831A-41B7-9935-B768448B78DFQ41813783-83EA8609-E128-4B1E-BD27-1530377DD660Q41866750-4B316E72-8B5C-4788-9CCE-4144F7442CE7Q50939437-01ED49FD-C276-4E82-8AEC-765ADD2CEAEDQ50994164-7DC6270D-5E4B-4634-B046-93EA14BB4885Q53000908-8C02ABB6-482B-4668-9CDF-0F659BE3532BQ53015871-DC7473DD-8A7E-4800-B4D8-026B5967CD72Q58804585-EEAA0E33-E187-4627-A530-D2A745A2AC8E
P2860
Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.
@ast
Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.
@en
type
label
Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.
@ast
Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.
@en
prefLabel
Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.
@ast
Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.
@en
P2093
P2860
P1476
Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.
@en
P2093
Andrea Krämer
Brigitte Zimmer
Juping Yuan
Klaus Strebhardt
Matthias Hofmann
Mourad Sanhaji
Nina-Naomi Kreis
Thorsten Berg
Wolfgang Reindl
P2860
P304
P356
10.1016/J.AJPATH.2011.06.031
P407
P577
2011-08-10T00:00:00Z